509 related articles for article (PubMed ID: 8111813)
1. Pharmaceutical patents and some international trade issues: Canada, the United States, and NAFTA.
Tancer RS
Clin Ther; 1993; 15(6):1177-84; discussion 1120. PubMed ID: 8111813
[TBL] [Abstract][Full Text] [Related]
2. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
[TBL] [Abstract][Full Text] [Related]
3. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
[TBL] [Abstract][Full Text] [Related]
4. Impact on access to medicines from TRIPS-Plus: a case study of Thai-US FTA.
Kessomboon N; Limpananont J; Kulsomboon V; Maleewong U; Eksaengsri A; Paothong P
Southeast Asian J Trop Med Public Health; 2010 May; 41(3):667-77. PubMed ID: 20578557
[TBL] [Abstract][Full Text] [Related]
5. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
Ghosh S
Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
[No Abstract] [Full Text] [Related]
6. The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution?
Silbermann JM
J Contemp Health Law Policy; 1996; 12(2):607-36. PubMed ID: 8666736
[No Abstract] [Full Text] [Related]
7. NAFTA and occupational health: a Canadian perspective. North American Free Trade Agreement.
Walker C
J Public Health Policy; 1997; 18(3):325-33. PubMed ID: 9360348
[TBL] [Abstract][Full Text] [Related]
8. A Critical Discourse Analysis of Intellectual Property Rights Within NAFTA 1.0: Implications for NAFTA 2.0 and for Democratic (Health) Governance in Canada.
Mohamed FA; Chaufan C
Int J Health Serv; 2020 Jul; 50(3):278-291. PubMed ID: 32019396
[TBL] [Abstract][Full Text] [Related]
9. Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here?
Lexchin J
Int J Health Serv; 2005; 35(2):237-56. PubMed ID: 15932005
[TBL] [Abstract][Full Text] [Related]
10. Intellectual property. Challenges to India's pharmaceutical patent laws.
Sampat BN; Shadlen KC; Amin TM
Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
[No Abstract] [Full Text] [Related]
11. [Intellectual property rights and right of access to medicines].
Velásquez G
Med Trop (Mars); 2006 Dec; 66(6):526-8. PubMed ID: 17286013
[TBL] [Abstract][Full Text] [Related]
12. USMCA (NAFTA 2.0): tightening the constraints on the right to regulate for public health.
Labonté R; Crosbie E; Gleeson D; McNamara C
Global Health; 2019 May; 15(1):35. PubMed ID: 31088499
[TBL] [Abstract][Full Text] [Related]
13. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.
Miller CP; Ullrich JW
Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591
[TBL] [Abstract][Full Text] [Related]
14. Biomedical patents and ethics: a Canadian solution.
Gold ER
McGill Law J; 2000 May; 45(2):413-35. PubMed ID: 12688288
[TBL] [Abstract][Full Text] [Related]
15. Sublicense or supply agreement? Supreme Court of Canada interpretation benefits generic pharmaceutical industry.
Burshtein S
Food Drug Law J; 1999; 54(1):73-91. PubMed ID: 11758562
[No Abstract] [Full Text] [Related]
16. Rx: higher prices.
Kosterlitz J
Natl J (Wash); 1993 Feb; 25(7):396-9. PubMed ID: 10125572
[TBL] [Abstract][Full Text] [Related]
17. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
[TBL] [Abstract][Full Text] [Related]
18. Intellectual property protection for plant-related inventions in Europe.
Fleck B; Baldock C
Nat Rev Genet; 2003 Oct; 4(10):834-8. PubMed ID: 14526379
[TBL] [Abstract][Full Text] [Related]
19. Patents, pills and politics: the Australia-United States Free Trade Agreement and the Pharmaceutical Benefits Scheme.
Harvey K
Aust Health Rev; 2004 Nov; 28(2):218-26. PubMed ID: 15527402
[TBL] [Abstract][Full Text] [Related]
20. Health policy or intellectual property policy? The fight over Bill C-91. Canadian Healthcare Association.
Int J Health Care Qual Assur Inc Leadersh Health Serv; 1997; 10(2-3):vii-x. PubMed ID: 10169229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
